Treatment of advanced cancers with Mevrometostat

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 clinical trial evaluates the safety and efficacy of Mevrometostat (PF-06821497) in patients with relapsed or refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC), and Follicular Lymphoma (FL). The study is designed as an open-label, multi-center trial that includes dose escalation and expansion phases, where Mevrometostat is administered either alone or in combination with standard of care treatments. The trial aims to determine the maximum tolerated dose (MTD) and assess the drug's antitumor activity across different patient cohorts, including those from Japan and China. Participants will be monitored for safety, pharmacokinetics, and treatment response.

Why it matters

Who can join: the full rules

Part 1 and Part 2 (Closed for enrollment).

Part 3 Key Inclusion Criteria:

* Histological or cytological diagnosis of castration resistant prostate cancer.
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
* Adequate bone marrow, renal, and liver function

Part 3 Key Exclusion Criteria:

* Prior irradiation to \>25% of the bone marrow.
* QTcF interval \>480 msec at screening.
* Hypertension that cannot be controlled by medications (\>150/90 mmHg despite optimal medical therapy).
* Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
* Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
* Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
* Prior enzalutamide within the last 4 weeks
* DDI SUBSTUDY:
* history of CHF or evidence of ventricular dysfunction
* fructose intolerance
* coadministration of CYP3A4 substrates

Where it's running

• Oncology Hematology West, PC dba Nebraska Cancer Specialists
  Omaha, Nebraska, United States Recruiting
• OU Health University of Oklahoma Medical Center
  Oklahoma City, Oklahoma, United States Recruiting
• Stephenson Cancer Center (chemo location)
  Oklahoma City, Oklahoma, United States Recruiting
• Carolina Urologic Research Center
  Myrtle Beach, South Carolina, United States Recruiting
• Parkway Surgery Center
  Myrtle Beach, South Carolina, United States Recruiting
• Sarah Cannon Research Institute - Pharmacy
  Nashville, Tennessee, United States Recruiting

+35 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager

  This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07795411

• 68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R

  This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07914764

• Exploration of whole-brain radiotherapy with PD-1 inhibitors for brain injury in SCLC

  This study tests whether adding PD-1 inhibitors to chemotherapy and prophylactic brain irradiation helps some small cell lung cancer patients protect the brain.

  Recruiting Guizhou Medical University · Guiyang, Guizhou · NCT07905937

• Propranolol with Adebrelimab and Platinum Chemotherapy in Small Cell Lung Cancer

  This early-phase trial tests whether adding propranolol to adebrelimab plus platinum chemotherapy is safe and may help treat small cell lung cancer in adults.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886047

• GI-102 with Pasritamig for metastatic prostate cancer

  This trial tests GI-102 together with Pasritamig to see if it is safe and may help men whose metastatic castration-resistant prostate cancer has progressed after prior hormonal therapy.

  Recruiting at 5 sites Phase 1/2 GI Innovation, Inc. · New York, New York and 5 other locations · NCT07871435

• IDP-121 plus chemotherapy in platinum-resistant small cell lung cancer

  This trial tests higher and higher doses of IDP-121 with chemotherapy to see if it is safe and workable for adults with advanced small cell lung cancer that progressed after first-line platinum therapy.

  Recruiting at 6 sites Phase 1/2 IDP Discovery Pharma S.L. · Barcelona and 9 other locations · NCT07864207

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.